[Impact of treatment compliance in chronic hepatitis B].

The incidence rate of chronic hepatitis B remains high in China. Antiviral therapy can significantly reduce the risk of progressive liver disease and hepatocellular carcinoma in patients with chronic hepatitis B. However, all current antiviral treatments can only inhibit HBV replication and not completely eliminate the hepatitis B virus, so antiviral therapy for chronic hepatitis B is probably a long-term or even lifelong treatment. Antiviral therapy compliance is essential for achieving long-term clinical benefits and preventing nucleot(s)ide drugs resistance. Herein, we analyzed the relevant factors of antiviral therapy compliance and their impact on CHB treatment and explored feasible programs that can improve compliance with nucleot(s)ide drug treatment by conducting a literature search using PubMed and Scopus with search terms including hepatitis B, compliance, nucleot(s)ide drugs, antiviral therapy, viral suppression, and drug resistance. 在中国慢性乙型肝炎（CHB）发病率一直居高不下，抗病毒治疗可以大大降低CHB患者进行性肝病和肝细胞癌的发生风险。然而，目前所有的抗病毒治疗只能抑制乙型肝炎病毒（HBV）的复制而不能彻底清除HBV，因此，CHB的抗病毒治疗是一个长期的甚至可能是终生的治疗。坚持抗病毒治疗对于实现CHB患者长期临床获益和预防对核苷（酸）类药物的耐药性至关重要。现使用PubMed和Scopus进行文献检索，检索词包括乙型肝炎、依从性、核苷（酸）类药物、抗病毒治疗、病毒抑制和耐药，分析抗病毒治疗依从性的相关因素及其对CHB治疗的影响，探索可以提高核苷（酸）类药物治疗依从性的可行方案。.